We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Euroapi SAS (EAPI) EUR1

Sell:€2.75 Buy:€2.78 Change: €0.05 (1.79%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:€2.75
Buy:€2.78
Change: €0.05 (1.79%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:€2.75
Buy:€2.78
Change: €0.05 (1.79%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Euroapi SAS is a France-based company. The Company is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. It offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc.), analgesics, etc. The Company also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. It has production sites located in France, the United Kingdom, Germany, Italy and Hungary.

Contact details

Address:
15, rue Traversiere
PARIS
75012
France
Telephone:
+33 (1) 89206200
Website:
https://www.euroapi.com/en

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EAPI
ISIN:
FR0014008VX5
Market cap:
€262.87 million
Shares in issue:
95.26 million
Sector:
Pharmaceuticals
Exchange:
Euronext Paris
Country:
France
Currency:
Euro
Indices:
n/a

Key personnel

  • Emmanuel Blin
    Chair of the Board
  • David Seignolle
    Chief Executive Officer
  • Olivier Falut
    Chief Financial Officer
  • Marion Santin
    Chief Legal, Compliance, and IP Officer
  • Guillaume Rosso
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.